Highlights Jacobio Pharmaceuticals Group Co., Ltd.

Equities

1167

KYG4987A1094

Market Closed - Hong Kong S.E. Other stock markets 01:38:17 17/05/2024 pm IST			5-day change	1st Jan Change
1.87 ^HKD	+1.08%		+0.54%	-48.34%

13/05	Jacobio Pharmaceuticals Reports Approval for Phase 3 Trial for Combination Therapy Between Glecirasib and Cetuximab	MT
10/05	Jacobio Pharmaceuticals Group Co., Ltd. Receives Approval of Registrational Phase III Clinical Trial of Glecirasib (Jab-21822) and Epidermal Growth Factor Receptor Inhibitor Erbitux in Patients with Colorectal Cancer	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Jacobio Pharmaceuticals Group Co., Ltd. Receives Approval of Registrational Phase III Clinical Trial of Glecirasib (Jab-21822) and Epidermal Growth Factor Receptor Inhibitor Erbitux in Patients with Colorectal Cancer	10/05	CI
Jacobio Pharmaceuticals Submits Cancer Treatment New Drug Application to Chinese Drug Regulator; Shares Surge 22%	07/05	MT
Jacobio Pharma Announces Its KRAS G12C Inhibitor Reached the Primary Endpoint	01/05	CI
Jacobio to Share Clinical Data of Anti-Tumor Drugs at US Convention	09/04	MT
Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting	09/04	CI
Jacobio Pharmaceuticals Narrows 2023 Loss on Lower R&D Expenses	01/04	MT
Jacobio Pharmaceuticals Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Jacobio Pharmaceuticals Group Co., Ltd. Receives US FDA Investigational New Drug Clearance for P53 Y220C Activator JAB-30300	01/03	CI
Jacobio Pharma Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor	18/02	CI
Jacobio Pharma Presents Data of Glecirasib in Patients with Pancreatic Cancer and Other Solid Tumors At the 2024 ASCO GI	20/01	CI
Jacobio Pharmaceuticals Group Co., Ltd. Announces Clinical Results in the Oral Abstract Session of Clinical Oncology Gastrointestinal Cancers Symposium	07/12	CI
Jacobio Pharma Presents Clinical Results of Glecirasib in Combination with Jab-3312 At Esmo	22/23/22	CI
Jacobio Pharmaceuticals Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	30/23/30	CI
Jacobio Pharmaceuticals Group Co., Ltd.'S In-House KRAS G12C Inhibitor Jab-21822 Granted Breakthrough Therapy Designation for Pancreatic Cancer Patients	07/23/07	CI
Jacobio Earmarks HK$100 Million for Share Buyback	24/23/24	MT
Jacobio Pharmaceuticals Group Co., Ltd. commences an Equity Buyback Plan for 79,356,228 shares, representing 10% of its issued share capital, under the authorization approved on June 8, 2023.	24/23/24	CI
Jacobio Pharmaceuticals Group Co., Ltd. Presents Clinical Results of Glecirasib in Colorectal Cancer	29/23/29	CI
Jacobio Pharmaceuticals Group Co., Ltd. Receives Investigational New Drug Approval for PARP7 Inhibitor JAB-26766 in China	08/23/08	CI
Chinese Regulator Approves Jacobio's Investigational New Drug Application for Tumor Treatment; Shares Climb 7%	04/23/04	MT
Jacobio Pharmaceuticals Group Co., Ltd. Receives Investigational New Drug Approval for LIF mAb JAB-BX300 IN CHINA	04/23/04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Jacobio Pharmaceuticals Group Co., Ltd.

Equities

1167

KYG4987A1094

Highlights

Filters